BIENAIME JEAN JACQUES

Form 4

November 05, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

January 31, Expires: 2005

OMB APPROVAL

Form 4 or Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Estimated average burden hours per response... 0.5

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading **BIENAIME JEAN JACQUES** Issuer Symbol **BIOMARIN PHARMACEUTICAL** (Check all applicable) INC [BMRN] (Last) (First) (Middle) 3. Date of Earliest Transaction _X_ Director 10% Owner X_ Officer (give title Other (specify (Month/Day/Year) below)

C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST.

> (Street) 4. If Amendment, Date Original Filed(Month/Day/Year)

> > (Zin)

11/02/2018

6. Individual or Joint/Group Filing(Check Applicable Line)

Chief Executive Officer

SAN RAFAEL, CA 94901

X Form filed by One Reporting Person Form filed by More than One Reporting Person

| <i>J</i> 2 11 1 1 1 2 11 2 11 | LL, CIT > 1701 |
|-------------------------------|----------------|
| (City) | (State) |

Stock

| (City) | (State) | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | |
|--------------------------------------|--------------------------------------|--|---|--------|------------------|--|---|---|-----------------------------------|--|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | Code V | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | (Instr. 4) | | |
| Common Stock | 11/02/2018(1) | | M | 1,500 | A | \$ 17.86 | 289,790 | D | | |
| Common Stock | 11/02/2018(1) | | S | 1,500 | D | \$ 97.88 | 288,290 | D | | |
| Common | | | | | | | 182,201 | I | Shares held by Jean-Jacques | |

Bienaime **Family Trust**

Edgar Filing: BIENAIME JEAN JACQUES - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transactic Code (Instr. 8) | (A) or Disposed of (D) (Instr. 3, 4, | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | |
|---|---|---|---|--|---|--|--------------------|---|--|
| | | | | Code V | and 5) (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to buy Common Stock) | \$ 17.86 | 11/02/2018 <u>(1)</u> | | M | 1,500 | 06/17/2009 | 12/16/2018 | Common Stock | 1,500 |

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO ST. X Chief Executive Officer

SAN RAFAEL, CA 94901

Signatures

/s/ Eric Fleekop, Attorney-in-Fact

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Trade made pursuant to a 10b5-1 plan executed on May 21, 2018.
- (2) Reflects the number of options outstanding after the transactions from this specific stock option grant.

Reporting Owners 2

Edgar Filing: BIENAIME JEAN JACQUES - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.